Is there cross-reactivity between aztreonam and penicillin in patients with a penicillin allergy?

Aztreonam Cross-Allergy with Penicillin

There is NO clinically significant cross-reactivity between aztreonam and penicillin—aztreonam can be safely administered to patients with penicillin allergy without prior testing, except in patients with a confirmed ceftazidime allergy. 1

Key Evidence from Guidelines

The 2022 Drug Allergy Practice Parameter provides the strongest guidance on this issue. The evidence demonstrates no cross-reactivity for IgE- or T-cell–mediated hypersensitivity between penicillin and aztreonam. 1 This is based on moderate-quality evidence and represents a conditional recommendation that patients with penicillin or cephalosporin allergy histories may receive aztreonam without prior testing.

The 2023 Dutch SWAB guideline corroborates this, stating that aztreonam can be used in patients with suspected immediate-type penicillin allergy without additional measures 2. For delayed-type non-severe penicillin allergies, aztreonam is also recommended as safe 2.

Structural Basis for Safety

The lack of cross-reactivity is explained by aztreonam's unique structure as a monobactam. Unlike penicillins and cephalosporins, aztreonam does not share the same core ring structure or side chains that typically cause cross-reactive allergic responses. The FDA label explicitly states that aztreonam is "rarely cross-reactive with other beta-lactam antibiotics and weakly immunogenic" 3.

Research Supporting Safety

Multiple prospective studies confirm this safety profile:

• A study of 212 patients with documented IgE-mediated penicillin hypersensitivity (positive skin tests) showed all patients tolerated aztreonam with negative skin tests 4
• In 214 patients with T-cell-mediated (delayed) hypersensitivity to penicillins, all had negative skin tests to aztreonam and tolerated challenges 5
• Cross-reactivity rates between penicillins and aztreonam are consistently reported as less than 1% in large prospective studies 6, 7

The Critical Exception: Ceftazidime

The only important caveat is ceftazidime allergy. Aztreonam shares an identical R1 side chain with ceftazidime, creating potential cross-reactivity between these two specific drugs 1, 2. If a patient has a confirmed allergy to ceftazidime (or cefiderocol, which has similar structural features), aztreonam should be avoided 2.

Clinical Algorithm

For patients with penicillin allergy requiring gram-negative coverage:

1. Confirm the allergy is to penicillin (not ceftazidime/cefiderocol)
2. Administer aztreonam without skin testing - this is safe regardless of:
   • Whether the penicillin reaction was immediate or delayed
   • The severity of the original reaction
   • How recently the reaction occurred
3. Only avoid aztreonam if:
   • Patient has confirmed ceftazidime allergy
   • Patient has confirmed cefiderocol allergy

Important Antibiotic Stewardship Considerations

While aztreonam is safe in penicillin-allergic patients, the guidelines emphasize it should not be overused 1. Aztreonam has significant limitations:

• No activity against gram-positive bacteria (requires vancomycin co-administration)
• Less effective against gram-negatives than alternatives like cefepime or piperacillin-tazobactam
• Increasing resistance rates
• Higher cost

Many patients labeled as "penicillin allergic" can actually tolerate penicillins or cephalosporins after proper allergy evaluation. Studies show 46.7% of aztreonam use may be inappropriate when patients have tolerated beta-lactams previously or have non-IgE-mediated reactions 8. Consider penicillin allergy testing or direct challenges to broader-spectrum beta-lactams when clinically appropriate, rather than defaulting to aztreonam.

Practical Implementation

The FDA label advises that while cross-reactivity is rare, aztreonam "should be administered with caution to any patient with a history of hypersensitivity to beta-lactams" 3. However, this cautionary language should be interpreted in the context of the robust guideline evidence showing safety without prior testing. In practice, this means:

• Standard administration without skin testing is appropriate
• Monitor for hypersensitivity as with any antibiotic
• Have emergency medications available (standard practice)
• Document the penicillin allergy details for future reference